TX-PLANVIEW
1.5.2024 15:01:33 CEST | Business Wire | Press release
Planview, the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced a series of platform innovations designed to accelerate the speed and impact of transformation by connecting project and product initiative data across the enterprise. These innovations enable bi-directional visibility and governance to create tighter alignment between strategies and teams, harness AI to enhance predictability and strategic decision-making, and deliver personalized user experiences to uplevel productivity.
“Organizations today are struggling with data sprawl and misalignment across their disparate teams and tools, with negative impact to the speed and success of their transformation efforts,” said Louise K. Allen, Chief Product Officer. “The platform innovations released today change how the enterprise leverages and connects data, transitioning it from an unusable repository to an invaluable asset. We are breaking down data silos by connecting strategic priorities and the teams delivering the work, enabling organization-wide visibility to keep outcomes front and center.”
Accelerate Outcomes with Comprehensive Data Visibility and Personalization
Introducing Planview.Me™, an easy-to-use, personalized platform experience designed to bring data, insights, and work together into a single view. With Planview.Me, teams and individuals across roles and personas can:
- Create configurable, unique views based on status, progress, stakeholder needs, and other data-oriented use cases.
- Reduce platform clicks to surface the right information at the right time with clear actions in a single view, for an improved user experience.
- Take action, investigate, respond, and react with a single click, increasing efficiency by having relevant data available at your fingertips.
- Bring data and insight transparency into all decisions and to all decision-makers within the organization.
Uplevel Your Productivity with Actionable AI-Insights and Expert Guidance
Planview® Copilot is now available across Strategic Portfolio Management, Enterprise Agile Planning (EAP), Value Stream Management (VSM), and Digital Product Development solutions, including the Planview® Portfolios, Planview® Viz, Planview® AdaptiveWork, and Planview® AgilePlace products.
First introduced as an Early Access release in September 2023, Planview Copilot users can:
- Converse with and question their data using natural language to glean insights, derive recommendations based on best practices, and inform strategic decisions.
- Instantly tap into decades of Planview knowledge, best practices, and key learnings.
- Surface hidden insights and delivery risks across multiple initiatives, value streams, products, and projects.
- Increase productivity by analyzing and synthesizing vast amounts of data in seconds.
Further boosting Planview’s AI-enabled platform capabilities, Planview is strengthening its early-warning systems with additional sentiment analysis and aggregation across key products, including Planview Portfolios, Planview® AgilePlace, and Planview® ProjectPlace. Sentiment analysis can:
- Create sentiment scores based on emotional tone across multiple comments and text entries to provide an overview of product, project, or work health.
- Analyze trends over time to understand whether large bodies of work reflect positive, neutral, or negative sentiments.
- Accurately reflect the status of the work outside of traditional red, amber, and green indicators.
“Connecting value stream data is a critical first step in creating the visibility needed to understand where your organizational challenges lie,” says Mik Kersten, Chief Technology Officer. “With Planview Copilot’s new skills and our robust early warning systems now embedded across the entire Planview Platform, we are empowering organizations with more than visibility – we are giving them the actionable insights that will shape their strategic decisions, drive productivity, and accelerate time to value for digital transformations.”
Redefine How Work Gets Done with Less Disruption and More Enterprise-wide Work Connectivity
With enhanced connectivity between Planview Portfolios and Planview ProjectPlace, Planview is bringing traditionally ungoverned work into the purview of portfolio leadership to ensure alignment, oversight, and governance while empowering teams to deliver projects with easy-to-use capabilities like Gantt, kanban, and document storage, in discrete workspaces with no manual status reporting. This enhancement drives greater team autonomy, allowing teams to continue working within their projects and programs without disruption, while providing leadership with the right level of visibility and oversight.
Finally, Planview introduces the Planview® Universal Connector, a strong addition to the 60+ software tool connectors it already has available. The Universal Connector enables organizations to automate and seamlessly integrate their third-party or homegrown software development tools directly into the Planview® Platform. By unlocking data siloed in disparate software delivery tools, data and work can flow directly into the Planview Platform, increasing data visibility and keeping productivity high without disrupting the native work and workflow processes of the delivery teams.
Additional Resources:
- Learn more about the Planview Platform
- Check out the Platform Demo to learn more about Planview.Me and Planview Copilot
- Learn more about Planview Copilot
- Register to attend Planview Accelerate on May 14-15, 2024, to learn more about Planview’s approach to Strategic Portfolio Management, Digital Product Development, Data, Generative AI, and Connected Work
About Planview
Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), enabling organizations to plan and deliver large-scale digital transformation initiatives. Planview empowers organizations to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic product and project initiatives deliver the desired business outcomes. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers and 2.7 million users globally, including 59 of the Fortune 100. Headquartered in Austin, Texas, Planview has over 1,400 employees worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429197434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
